Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -15.96%.

  • Legend Biotech's EBITDA Margin rose 2363.00% to -15.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.00%, marking a year-over-year increase of 6867.00%. This contributed to the annual value of -0.40% for FY2024, which is 8418.00% up from last year.
  • As of Q3 2025, Legend Biotech's EBITDA Margin stood at -15.96%, which was up 68.70% from -50.98% recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's EBITDA Margin ranged from a high of 21,716.39% in Q4 2024 and a low of -184,760.17% during Q4 2023.
  • Over the past 3 years, Legend Biotech's median EBITDA Margin value was -50.98% (recorded in 2025), while the average stood at -14,898.86%.
  • Per our database at Business Quant, Legend Biotech's EBITDA Margin crashed by 18,425,141bps in 2023 and then surged by 20,647,656bps in 2024.
  • Quarterly analysis of 5 years shows Legend Biotech's EBITDA Margin stood at -228.07% in 2021, then slumped by 28,068bps to -508.75% in 2022, then plummeted by 18,425,141bps to -184,760.17% in 2023, then surged by 20,647,656bps to 21,716.39% in 2024, then spiked by 2,363bps to -15.96% in 2025.
  • Its EBITDA Margin stands at -15.96% for Q3 2025, versus -50.98% for Q2 2025 and 31.13% for Q1 2025.